BioSpace News Archive

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 first quarter ended June 30, 2023.

Zomedica Corp., a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, reported consolidated financial results for the quarter ended June 30, 2023.

IntelGenx Corp. announced that it has entered into a binding term sheet agreement for the packaging of a pharmaceutical oral film product that its undisclosed CDMO customer is planning to commercialize in the United States.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an overview of recent operational highlights.

Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided a corporate update.

Akebia Therapeutics®, Inc. announced that it has filed with the U.S. Securities and Exchange Commission a Form 12b-25 Notification of Late Filing with regard to its Quarterly Report on Form 10Q for the quarter ended June 30, 2023.

Extendicare Inc. reported results for the three and six months ended June 30, 2023.

Mirum Pharmaceuticals, Inc. announced that on August 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 34,200 shares of common stock and 17,100 restricted stock units to six new employees under Mirum’s 2020 Inducement Plan.

OnPoint today announced that it will participate in the 2023 8th Annual Needham Virtual Medtech and Diagnostics Conference, which will take place on August 15th, 2023.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the second quarter June 30, 2023.